Tacere expects IND-enabling studies to begin soon, and Oncolys gains Asian rights.

Oncolys BioPharma signed an agreement to develop Tacere Therapeutics’ drug candidate for the treatment of HCV. TT-033 is an RNAi-based product.


Under this agreement, Oncolys has been granted an option to acquire the Asian rights for TT-033. “HCV continues to be a significant public health crisis in Japan, China, and Korea, and we look forward to Oncolys’ expert guidance along the regulatory and marketing path in Asia,” remarks Sara M. Hall, Tacere’s president and CEO.


Tacere reports that it will begin IND-enabling studies on TT-033 shortly and plans to enter Phase I trials in late 2008.

Previous articleDrug Target Identification and Validation
Next articleInvestigators Discover that Buckyballs Block Allergies